CanaQuest Medical Corp

CanaQuest is a precision neuroscience platform company advancing CQ-001 for genetically defined rare pediatric epilepsies, FDA 505(b)(2), referencing an approved drug. Western University research grounds its multi-pathway Dual-PPAR mechanism. University of Toronto preclinical studies, supported by the Ontario Brain Institute, showed ~35% greater anticonvulsant potency than that drug's active ingredient. The mechanism extends to TBI/concussion, Alzheimer's, neurodegeneration & neuroinflammation.